
$32
0 reviews
Neuramis Deep Lidocaine – Advanced Dermal Filler for Deep Wrinkle Correction and Facial Contouring
Product Description
Neuramis Deep Lidocaine is a premium hyaluronic acid-based dermal filler developed by Medytox, South Korea. Engineered with SHAPE (Stabilized Hyaluronic Acid & Purification Enhancement) technology, it ensures high purity and stability. This filler is designed to address moderate to deep facial wrinkles and enhance facial contours, providing natural-looking results with minimal discomfort due to its lidocaine content.
Formulation
-
Hyaluronic Acid Concentration: 20 mg/mL of cross-linked hyaluronic acid
-
Lidocaine Content: 0.3% for pain reduction during injection
-
Technology: SHAPE technology for enhanced purity and stability
-
Cross-Linking: Two-step cross-linking process for prolonged effect
Benefits
-
Smooths moderate to deep facial wrinkles and folds
-
Enhances facial volume and contours
-
Provides immediate and natural-looking results
-
Minimizes discomfort during treatment due to lidocaine
-
High patient satisfaction with long-lasting effects
Indications
-
Correction of deep nasolabial folds
-
Augmentation of cheeks, chin, and jawline
-
Enhancement of lip volume and contour
-
Treatment of forehead lines and glabellar frown lines
-
Improvement of marionette lines and perioral wrinkles
Scope of Application
Neuramis Deep Lidocaine is suitable for:
-
Facial contouring and volume restoration
-
Deep wrinkle correction
-
Lip augmentation
-
Treatment of aging signs in the face, neck, and hands
Duration of Effect
The effects of Neuramis Deep Lidocaine typically last between 9 to 12 months. Maintenance treatments can be scheduled every 3 to 6 months to sustain optimal results.
Packaging and Specifications
-
Packaging: 1 x 1.0 mL pre-filled syringe
-
Needle: 27G x ½” (13mm) Ultra-Thin Wall (UTW) needle
-
Injection Depth: Mid to deep dermis
-
Storage Conditions: Store at 2°C – 25°C; protect from direct sunlight; do not freeze
-
Shelf Life: 24 months from the manufacturing date
-
Manufacturer: Medytox Co., Ltd., South Korea